Pleural Effusion – Pipeline Review, H2 2012

Pleural Effusion – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pleural Effusion - Pipeline Review, H2 2012', provides an overview of the Pleural Effusion therapeutic pipeline. This report provides information on the therapeutic development for Pleural Effusion, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pleural Effusion. 'Pleural Effusion - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pleural Effusion.
- A review of the Pleural Effusion products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pleural Effusion pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pleural Effusion.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pleural Effusion pipeline depth and focus of Pleural Effusion therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pleural Effusion Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Pleural Effusion 7
Pleural Effusion Therapeutics under Development by Companies 9
Pleural Effusion Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pleural Effusion Therapeutics – Products under Development by Companies 13
Pleural Effusion Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Pleural Effusion Therapeutics Development 15
Simcere Pharmaceutical Group 15
Nobelpharma Co., Ltd. 16
Pleural Effusion – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
BG00001 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
SCH 721015 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Pemetrexed + Carboplatin + Bevacizumab - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
NPC-05 Talc - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Nitric Oxide - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Endostar + Cisplatin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Doxycycline - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Pleural Effusion Therapeutics - Dormant Products 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables
Number of Products Under Development for Pleural Effusion, H2 2012 7
Products under Development for Pleural Effusion – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Simcere Pharmaceutical Group, H2 2012 15
Nobelpharma Co., Ltd., H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Pleural Effusion Therapeutics – Dormant Products 30

List of Figures
Number of Products under Development for Pleural Effusion, H2 2012 7
Products under Development for Pleural Effusion – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22